Biol Reprod Lalor Postdoctoral Fellowships -- Application Deadline January 15, 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

BOR - Papers in Press, published online ahead of print February 25, 2004.
Biol Reprod 2004, 10.1095/biolreprod.103.025411
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
71/1/170    most recent
biolreprod.103.025411v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guzeloglu, A.
Right arrow Articles by Thatcher, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guzeloglu, A.
Right arrow Articles by Thatcher, W. W.
Agricola
Right arrow Articles by Guzeloglu, A.
Right arrow Articles by Thatcher, W. W.
BIOLOGY OF REPRODUCTION 71, 170–176 (2004)
DOI: 10.1095/biolreprod.103.025411
© 2004 by the Society for the Study of Reproduction, Inc.

Female Reproductive Tract

Interferon-{tau} Induces Degradation of Prostaglandin H Synthase-2 Messenger RNA in Bovine Endometrial Cells Through a Transcription-Dependent Mechanism1

Aydin Guzeloglu3, Prem Subramaniam4, Frank Michel3, and William W. Thatcher2,3

Department of Animal Sciences3 Department of Microbiology and Cell Science,4 University of Florida, Gainesville, Florida 32611-0910


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A series of experiments were undertaken to examine the effects of interferon (IFN)-{tau} on regulation of prostaglandin H synthase (PGHS)-2 mRNA in bovine endometrial (BEND) cells as a means to elucidate the actions of IFN-{tau} to maintain pregnancy. The objective was to determine if IFN-{tau} mediates posttranscriptional regulation of PGHS-2 mRNA. Cells were treated with phorbol 12,13-dibutyrate (PdBu) for 3 h to induce PGHS-2 mRNA expression. Actinomycin D (0 or 1 µg/ml) or the p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580 (1 µM), were added at 3 h, followed by addition of IFN-{tau} (0 or 50 ng/ml) at 3.5 h and extraction of RNA at 4.5 h. The concentrations of PGHS-2 mRNA were stable between 3 and 4.5 h regardless of actinomycin D. Simultaneous treatment of PdBu-treated cells with actinomycin D and SB203580 (1 µM) decreased PGHS-2 mRNA. Addition of IFN-{tau} (50 ng/ml) reduced PGHS-2 mRNA, which was not observed when actinomycin D was present. Concurrent treatments of cells with SB203580 and IFN-{tau} (5 ng/ml) decreased concentrations of PGHS-2 mRNA in an additive manner. Although IFN-{tau} reduced PGHS-2 mRNA concentrations, phosphorylation of p38 MAPK was induced by IFN-{tau}, PdBu, and PdBu combined with IFN-{tau} after 10 min of treatment. Both the p38 MAPK inhibitor and IFN-{tau} decreased prostaglandin F2{alpha} secretion, and decreases were additive when the two were given together. In summary, activation of p38 MAPK by PdBu is required for continued presence of PGHS-2 mRNA and secretion of prostaglandin F2{alpha} in BEND cells. Interferon-{tau} mediates a transcription-dependent mechanism, which induces degradation of PGHS-2 mRNA. However, the consequences of an IFN-{tau}-induced activation of p38 MAPK warrant further investigation, because inhibition of p38 MAPK caused a degradation of PGHS-2 mRNA.

cytokines, female reproductive tract, kinases, signal transduction, uterus


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The prostaglandin H synthase (PGHS) enzyme catalyzes the conversion of arachidonic acid to prostaglandin (PG) H2 and is a rate-limiting enzyme for PG production. The two isoforms of PGHS are designated as PGHS-1, which is constitutively expressed, and PGHS-2, which is the inducible isoform [1]. Expression of PGHS-2 can be induced in many different cell types and tissues. Examples include cytokines acting on colonic epithelial cells [2] and endothelial cells [3], FSH and LH in ovarian follicles [4], endotoxins in macrophages [5], and tumor promoters acting on hepatocytes [6].

Normally, PGHS-2 is undetectable in most mammalian tissues, and expression occurs very rapidly. Thus, PGHS-2 is classified as an immediate early gene. In many cases, rapid induction of expression leads to rapid degradation of the mRNA and its protein [1]. Its sustained presence in tissues involves several regulatory mechanisms. In fibroblasts, for example, increased PGHS-2 mRNA results from a higher rate of PGHS-2 gene transcription [7]. Posttranscriptional regulation is also important. For example, serum withdrawal in mammary carcinoma cells increases the stability of PGHS-2 mRNA and, thus, its half-life [8]. Similarly, interleukin-1{alpha} acts on a human cell line to increase the stability of PGHS-2 mRNA [9]. Thus, posttranscriptional mechanisms are required for the sustained presence of PGHS-2 mRNA in cells. Conversely, it is possible that acutely induced inhibition of PGHS-2 gene expression may involve stimulation of PGHS-2 mRNA degradation.

Interferon (IFN)-{tau} is classified as a type I IFN and is secreted by trophoblastic cells of the growing embryo in ruminants [10–12]. It binds to type I IFN receptors on endometrial cells [13] and suppresses oxytocin-induced secretion of PGF2{alpha} in vivo [14] and from primary endometrial epithelial cells in culture [15, 16]. Suppression of PGF2{alpha} secretion leads to maintenance of the corpus luteum (CL) to sustain a pregnancy [17]. Studies with a bovine endometrial (BEND) cell line [18, 19] and primary epithelial cells [16] demonstrated that IFN-{tau} decreases concentrations of PGHS-2 mRNA and protein and subsequent PGF2{alpha} secretion. It was suggested that IFN-{tau} may inhibit transcript of the PGHS-2 gene, because the promoter for the PGHS-2 gene has IFN stimulatory response elements (ISREs) [19, 20]. Type I IFNs also induce transcription of IFN regulatory factor (IRF)-1 and IRF-2 [21], and IRF-1 directly increases expression of IRF-2 [22]. In BEND cells, IFN-{tau} stimulates IRF-1 expression [23]. However, IRF-2 negatively regulates IRF-1 [21]. The IRF-2 is a potent transcriptional inhibitor of IFN-stimulated genes and is expressed in the luminal epithelium of the ovine uterus [24]. Thus, IRF-2 might affect PGHS-2 mRNA expression negatively in BEND cells. An alternative negative regulatory mechanism could be an indirect effect mediated through IFN-{tau}-induced gene transcription of other endometrial proteins that alter transcription rate, turnover of PGHS-2 mRNA, and/or functionality of PGHS-2 protein.

The p38 mitogen-activated protein kinase (MAPK) enzyme regulates the stability of PGHS-2 mRNA. Inhibition of p38 MAPK in different cell types, induced by a variety of agents, resulted in reduced expression and/or increased turnover of PGHS-2 mRNA [8, 25, 26]. In human monocytes [27] and human alveolar macrophages [5], endotoxin-induced expression of PGHS-2 mRNA was reduced by p38 MAPK inhibitors, suggesting that p38 MAPK activity is required for stabilization of PGHS-2 mRNA. Agents that stimulate expression of PGHS-2 mRNA also induce p38 activity [27]. Use of ceramide in fibroblasts induced activity of extracellular signal-regulated kinase (ERK)/MAPK and p38 MAPK [28]. Similarly, use of phorbol 12,13-dibutyrate (PdBu), a tumor-promoting agent, induced activation of protein kinase C (PKC) and, subsequently, ERK/MAPK and p38 MAPK in human astrocytoma cells [29]. Use of PdBu in BEND cells also activates PKC [30] and leads to activation of ERK/MAPK [19], expression of PGHS-2 mRNA, and secretion of PGF2{alpha} [18, 19].

Treatment of primary bovine edometrial epithelial [31] and BEND cells [18] with IFN-{tau} resulted in a decrease in PGHS-2 mRNA expression. The stability of PGHS-2 mRNA may be regulated by p38 MAPK, and it needs to be characterized within endometrial cells relative to IFN-{tau} regulation of PGHS-2 mRNA. Our hypothesis is that IFN-{tau} decreases the concentration of PGHS-2 mRNA via regulation of mRNA degradation because of an IFN-{tau}-induced decrease in p38 MAPK activity within endometrial cells.

The objectives of the present study were to determine if p38 MAPK is required for sustained presence of PGHS-2 mRNA induced by PdBu and if IFN-{tau} increases the degradation of PGHS-2 mRNA in BEND cells.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials

Recombinant bovine IFN-{tau} (1.08 x 107 U antiviral activity/mg) was a generous gift from Dr. R. Michael Roberts (University of Missouri, Columbia, MO). TRIzol reagent was purchased form Invitrogen Corporation (Carlsbad, CA). Polystyrene tissue-culture Costar six-well plates and culture dishes (100 mm x 20 mm) were from Corning Glass Works (Corning, NY). Polystyrene cell-culture flasks (185 cm2) were from Sarstedt, Inc. (Newton, NC). Acrylamide, N,N'-methylenebisacrylamide, sodium dodecyl sulfate, and Nonidet-P40 were purchased from BDH Laboratory Supplies (Poole, U.K.). Coomassie brilliant blue, bromophenol blue, ß-mercaptoethanol, NaOH, Tris, Tris-HCl, TEMED, ammonium persulfate, formaldehyde, acetic acid, Tween 20, NaCl, EDTA, NaF, glycerol, glycine, and methanol were from Fisher Scientific (Pittsburgh, PA). The PdBu, Ham F-12, Eagle minimum essential medium, antibiotic-antimycotic solution (AbAm), insulin, D-valine, horse serum, aprotinin, leupeptin, pepstatin, Na4P2O7, EGTA, Na3VO4, PMSF, actinomycin D, and BSA were from Sigma Chemical Co. (St. Louis, MO). Fetal bovine serum was from Atlanta Biologicals (Norcross, GA). The p38 MAPK inhibitor, SB203580, was received from Calbiochem (La Jolla, CA). Isotopically labeled [5,6,8,11,12,14,15-3H]PGF2{alpha} (212 Ci/mol) and nitrocellulose membranes (Hybond-ECL) were from Amersham Corporation (Arlington Heights, IL). Antibody for phosphorylated p38 MAPK was from Promega (Madison, WI). Antibody for PGHS-2 was from Cayman Chemical (Ann Arbor, MI). Radiographic film was from Eastman Kodak (X-Omat Blue XB-1; Rochester, NY). Enhanced chemiluminescence kit (Renaissance Western Blot Chemiluminescence Reagent Plus) was from NEN Life Science Products (Boston, MA).

BEND Cell Culture and Experimental Models

Isolation of BEND cells from a primary cell culture has been described by Staggs et al. [32]. The cell line is deposited and characterized by the American Type Culture Collection (ATCC; no. CRL-2398; Manassas, VA). The ATCC describes methodology for subculturing, propagation, and freezing and for products produced by the cells. The BEND cells were cultured in a T-185 flasks, 100-mm dishes, or six-well plates (1 x 104 cells/cm2) in culture medium (40% Ham F-12, 40% minimal essential medium [MEM], 10 ml/L of AbAm, 200 U/L of insulin, 0.0343 g/L of D-valine, 10% fetal bovine serum, and 10% horse serum). Cells were grown to 90% confluency at 37°C under a humidified atmosphere containing 95% air and 5% CO2, washed in serum-free medium, and cultured for an additional 24 h in serum-free medium. At the end of the 24-h period (designated as 0 h), cells were washed again, and treatments were added to cells in serum-free medium. When examining degradation of PGHS-2 mRNA, at 0 h PdBu (100 ng/ml) was added to cells for 3 h to induce PGHS-2 mRNA expression. One group of cells was sampled at 3 h. In the remaining groups, actinomycin D (0 or 1 µg/ml) was added at 3 h, followed by addition of IFN-{tau} (0 or 50 ng/ml) 0.5 h later, or at 3.5 h after stimulation with PdBu (i.e., cells were pretreated with or without actinomycin D for a 30-min period before addition of IFN-{tau}). Cells were incubated an additional 1 h following IFN-{tau} treatment. An additional group received both SB203580 (1 µM) and actinomycin D concurrently at 3 h without subsequent treatment with IFN-{tau}. Cells were harvested for RNA extraction at the end of the 4.5-h experimental period after stimulation with PdBu. This experiment was replicated three times, and each treatment was duplicated in each replicate.

When examining interacting effects of p38 MAPK inhibitor and IFN-{tau} to reduce PGHS-2 mRNA concentration, a low dose of IFN-{tau} (5 ng/ml) was used, which decreased the steady-state concentrations of PGHS-2 mRNA by approximately 50% (unpublished observations). At 0 h, cells were stimulated with PdBu (100 ng/ml). At 3 h, SB203580 (0 or 1 µM) was added to the cells. At 3.5 h, IFN-{tau} (0 or 5 ng/ml) was added, and cells were collected at 4.5 h for RNA extraction. This experiment was replicated twice, and each treatment was duplicated in each replicate.

To characterize p38 MAPK phosphorylation, BEND cells were untreated or were treated with PdBu and IFN-{tau}. At 0 h, cells were treated with either PdBu (0 or 100 ng/ml) or IFN-{tau} (0 or 50 ng/ml) for 10 min in a 2 x 2 factorial design. The untreated cells served as a control. At the end of the treatment periods, cells were harvested for protein extraction. This experiment was replicated twice, and each treatment was duplicated in each replicate.

When examining PGF2{alpha} secretion, BEND cells were cultured in six-well plates. Following a 24-h starvation period, cells were pretreated with SB203580 (0 or 1 µM) for 1 h (i.e., –1 h). At 0 h, PdBu (100 ng/ml) was added with IFN-{tau} (0 or 50 ng/ml). Medium was sampled at 6 h for determination of PGF2{alpha} concentration. Concentrations of PGF2{alpha} were measured in medium as described below. This experiment was replicated three times, and each treatment was done in triplicate in each replicate.

RNA Isolation and Northern Blot Analysis

Total RNA was isolated from confluent BEND cells with TRIzol according to the manufacturer's specifications. Twenty micrograms of cellular RNA was fractionated in a 1.5% agarose-formaldehyde gel, stained with ethidium bromide, blotted to BioTrans nylon membrane, and hybridized. The PGHS-2 [33] cDNA was a gift from Dr. J. Sirois (University of Montreal, St. Hyacinthe, QC, Canada). The P32-labelled PGHS-2 cDNA was used for Northern blot analyses of the mRNA.

Preparation of Cell Extracts

At the end of the culture periods, plates were transported to a cold room (4°C). The culture medium was discarded, and the cells were rinsed twice in ice-cold PBS. Cells were scraped from plates in the presence of 1 ml of whole-cell extract buffer (50 mM Tris [pH 8.0], 300 mM NaCl, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 10% [v/v] glycerol, 0.5% [v/v] NP-40, and 10 µg/ml each of aprotinin, leupeptin, and pepstatin) and then placed on a rotator (LabQuake Labindustries, Berkeley, CA) for 30 min at 4°C. Lysates were then centrifuged at 10 000 x g for 10 min and the supernatant was collected. Protein concentrations were determined in supernatants according to the method described by Bradford [34].

Western Blot Analysis of Phosphorylated p38 MAPK

Fifty micrograms of protein was loaded onto 10% acrylamide denaturing gel, submitted to SDS-PAGE, and electrophoretically transferred to nitrocellulose membranes. Membranes were blocked for 2 h at room temperature in 1% (w/v) BSA in Tris-buffered saline (TBS; 10 mM Tris-base, pH 7.5) and probed with antibodies against phosphorylated p38 MAPK diluted (1:1000) in 0.1% BSA in TBS with 0.1 % Tween 20 (TBST) for 2 h at room temperature. Blots were then incubated with the secondary antibody (anti-rabbit immunoglobulin G; 1:5000 dilution in 0.1% BSA in TBST) for 1 h. Proteins were detected by chemiluminescence and analyzed by densitometry (AlphaImager 2000; Alpha Innotech Corporation, San Leandro, CA).

Radioimmunoassay for PGF2{alpha}

Concentrations of PGF2{alpha} were measured in medium according to the method described by Danet-Desnoyers et al. [15]. The assay was validated for serum-free medium [18]. The anti-PGF2{alpha} antiserum utilized was characterized by Dubois and Bazer [35] and diluted 1:5000 (Tris buffer). Twenty-five microliters of each sample was diluted to a 100-µl assay volume with 50 mM Tris-HCl (pH 7.5; Tris buffer). Standard curves were prepared with known amounts of nonradioactive PGF2{alpha} (5–1000 pg/ml) diluted in Tris buffer (100 µl).

Statistical Analysis

Data were analyzed by least-squares analysis of variance using the General Linear Models (GLM) procedure of SAS [36]. For abundance of PGHS-2 mRNA in Northern blots and phosphorylated p38 MAPK in Western blots as well as concentrations of PGF2{alpha}, the statistical model included the effects of treatment, replicate, treatment by replicate interaction, and residual error. The term treatment by replicate was the error term for treatment. For mRNA analysis, abundance of glyceraldehyde phosphate dehydrogenase mRNA was used as a covariate to adjust for any differences among samples in loading concentrations. Least-squares means were compared using the Pdiff statement. Preplanned orthogonal contrasts were performed to compare main effects of treatments (p38 MAPK inhibitor vs. no p38 MAPK inhibitor, IFN-{tau} vs. no IFN-{tau}, and interaction of p38 MAPK inhibitor by IFN-{tau}).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Effect of IFN-{tau} and p38 MAPK on Degradation of PGHS-2 mRNA

At 4.5 h, cells exposed to PdBu and to PdBu with actinomycin D had the same PGHS-2 mRNA concentration as cells harvested at 3 h after PdBu treatment (Fig. 1). Addition of IFN-{tau} for a 1-h period beginning at 3.5 h reduced the abundance of PGHS-2 mRNA (P < 0.01) (Fig. 1), and the IFN-{tau}-induced reduction in PGHS-2 mRNA was blocked by addition of actinomycin D (P < 0.01) (Fig. 1). The IFN-{tau} caused a reduction in existing PGHS-2 mRNA concentration, because expression of PGHS-2 mRNA at 4.5 h of PdBu stimulation was comparable to that at 3 h of PdBu stimulation. Inhibition of p38 MAPK caused by the addition of SB203580 along with PdBu and actinomycin D led to a reduction in PGHS-2 mRNA compared to cells treated with PdBu and actinomycin D together (P < 0.01) (Fig. 1). Thus, p38 MAPK appeared to be essential to maintaining stability of the PGHS-2 mRNA. The p38 MAPK inhibitor-induced increase in degradation of PGHS-2 mRNA was comparable to that induced by IFN-{tau}. Collectively, experimental results indicate that IFN-{tau} increased the degradation of PGHS-2 mRNA through a mechanism that requires gene transcription. In contrast, p38 MAPK appears to directly sustain the concentration of PGHS-2 mRNA in a manner that is not transcriptionally dependent.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 1. BEND cells were stimulated by PdBu (100 ng/ml) for 3 h and received subsequent treatments with IFN-{tau}, SB203580, and actinomycin D to monitor PGHS-2 mRNA degradation. Autoradiographic bands were scanned for densitometric values. Data were analyzed using values for glyceraldehyde phosphate dehydrogenase as a covariate and expressed as the least-squares mean ± SEM. Treatment of PdBu-stimulated cells with IFN-{tau} for a 1-h period beginning at 3.5 h reduced the abundance of PGHS-2 mRNA (P < 0.01), and the IFN-{tau}-induced reduction in PGHS-2 mRNA was blocked by addition of actinomycin D (P < 0.01). Addition of the p38 MAPK inhibitor, SB203580, along with PdBu and actinomycin D reduced steady-state concentrations of PGHS-2 mRNA compared to cells treated with PdBu and actinomycin D combined (P < 0.01). Means with different letters are significantly different (P < 0.01)

Complementary Effects of IFN-{tau} and the p38 MAPK Inhibitor to Reduce PGHS-2 mRNA

At the end of the starvation period (0 h), cells were stimulated with PdBu (100 ng/ml). At 3 h, SB203580 (0 or 1 µM) was added to the cells. At 3.5 h, IFN-{tau} (0 or 5 ng/ ml) was added and cells collected at 4.5 h for RNA extraction. The PdBu-induced concentrations of PGHS-2 mRNA were reduced by the p38 MAPK inhibitor (P < 0.01) and IFN-{tau} (P < 0.01) in an additive manner (Fig. 2).



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 2. BEND cells were stimulated with PdBu (100 ng/ml) for 3 h. At 3 h, SB203580 (0 or 1 µM) was added to the cells. At 3.5 h, IFN-{tau} (0 or 5 ng/ml) was added. Cells were collected at 4.5 h for RNA extraction. Autoradiographic bands were scanned for densitometric values. Data were analyzed using values for glyceraldehyde phosphate dehydrogenase as covariate and expressed as the least-squares mean ± SEM. The PdBu-induced, steady-state concentrations of PGHS-2 mRNA were reduced by both SB203580 and IFN-{tau} (P < 0.01). Main effects of SB203580 (P < 0.01) and IFN-{tau} (P < 0.01) were detected. Means with different letters are significantly different (P < 0.01)

PdBu-Induced Phosphorylation of p38 MAPK

Treatment of cells with either PdBu or IFN-{tau} for 10 min induced phosphorylation of p38 MAPK (P < 0.01) (Fig. 3). The antibody recognizes p38 MAPK that is phosphorylated on threonine-180 and tyrosine-182 residues. Concurrent addition of PdBu and IFN-{tau} stimulated phosphorylation of p38 MAPK, but no more than when given separately.



View larger version (8K):
[in this window]
[in a new window]
  		FIG. 3. BEND cells were treated with either PdBu (0 or 100 ng/ml) or IFN-{tau} (0 or 50 ng/ml) for 10 min in a 2 x 2 factorial design. At the end of the treatment periods, cells were harvested for protein extraction. Autoradiographic bands were scanned to have densitometric values. Data were analyzed and expressed as the least-squares mean ± SEM. Treatment of cells with either PdBu or IFN-{tau} for 10 min induced phosphorylation of p38 MAPK (P < 0.01). Means with different letters are significantly different (P < 0.01)

Involvement of p38 MAPK in PdBu-Induced PGF2{alpha} Secretion from BEND Cells

After starvation, cells were pretreated with SB203580 (0 or 1 µM) for 1 h (i.e., –1 h). At 0 h, PdBu (100 ng/ml) was added concurrently with IFN-{tau} (0 or 50 ng/ml). Medium was sampled at 6 h for determination of PGF2{alpha} concentration. The p38 MAPK inhibitor (1 µM) decreased PdBu-induced PGF2{alpha} secretion from BEND cells at 6 h (P < 0.01) (Fig. 4). The IFN-{tau} also reduced significantly the PdBu-induced secretion at 6 h (P < 0.01) (Fig. 4). Treatment with both the inhibitor and IFN-{tau} caused a further reduction in the secretion of PGF2{alpha} (P < 0.05) (Fig. 4). Main effects of p38 MAPK inhibitor and IFN-{tau} were detected (P < 0.01). Responses indicated an additive inhibitory effect of the p38 MAPK inhibitor and IFN-{tau} on secretion of PGF2{alpha}.



View larger version (9K):
[in this window]
[in a new window]
  		FIG. 4. Effect of IFN-{tau} and SB203580 on PdBu-induced PGF2{alpha} secretion in BEND cells. Cells were pretreated with SB203580 (0 or 1µM) for 1 h, and then PdBu (100 ng/ml) and IFN-{tau} (0 or 50 ng/ml) were added for an additional 6 h. Data were analyzed and expressed as the least-squares mean ± SEM. The p38 MAPK inhibitor, SB203580 (1 µM), decreased PdBu-induced PGF2{alpha} secretion from BEND cells at 6 h (P < 0.01). The IFN-{tau} also significantly reduced PdBu-induced secretion at 6 h (P < 0.01). Combination of both treatments caused a further reduction in the secretion of PGF2{alpha} (P < 0.05). Means with different letters are significantly different (a vs. b and c, P < 0.01; b vs. c, P < 0.05)


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Treatment of BEND cells with PdBu induces ERK/ MAPK activity, and the MEK1 inhibitor, PD98059, completely blocked PdBu-stimulated PGHS-2 mRNA transcription and PG secretion [19]. The PdBu-induced activation of PKC in BEND cells [30] causes a subsequent activation of the Raf1/MEK1/ERK1/2 signaling pathway with transcription of c-jun and c-fos transcription factors leading to the transcription of PGHS-2 mRNA [19]. The dependency on PKC activation is further supported by the observation that inhibition of PKC activity by a specific inhibitor (e.g., GF109203X) blocks the PdBu stimulation of PGF2{alpha} secretion in BEND cells. Indeed, PKC{alpha} appears to be the activated isotype of PKC family in BEND cells [30].

In the present series of experiments, the importance of p38 MAPK activity for PdBu-induced secretion of PGF2{alpha} was evident in BEND cells. Treatment of cells with PdBu induced a rapid phosphorylation of p38 MAPK at 10 min. Furthermore, preincubation of cells for 1 h with a specific p38 MAPK inhibitor, 1 µM SB203580, decreased PGF2{alpha} secretion measured at 6 h after PdBu stimulation. The SB203580 is a highly specific, cell-permeable inhibitor of p38 kinase and does not inhibit significantly other members of the MAPK family, such as ERKs and c-jun N-terminal kinase (JNK), even at 100 µM concentrations (Calbiochem). Dean et al. [27] concluded that the effects of SB203580, at concentrations up to 2 µM, are highly specific for the inhibition of p38 MAPK. A pivotal regulatory role of p38 MAPK in response to PdBu has been emphasized by other studies in a variety of cell types for reducing turnover of mRNAs [29, 37, 38]. Indeed, in the present experiment, inhibition of p38 MAPK with SB203580 increased degradation of PGHS-2 mRNA.

The PGHS-2 is one of the critical enzymes for production of PGF2{alpha} by BEND cells. It is an immediate response gene, the expression of which is evident by 30 min after PdBu stimulation [19]. However, PGHS-2 mRNA is degraded rapidly or is highly unstable, with a half-life of 1 h in human lung and kidney cells [39]. Ristimaki et al. [9, 39] suggested that posttranscriptional regulation is important to sustain a PGHS-2 presence and proposed that anti-inflammatory responses induced by glucocorticoids increase turnover of PGHS-2 mRNA. Indeed, a role for dexamethasone was indicated for the destabilization of PGHS-2 mRNA via an inhibition of p38 MAPK [40]. Several other studies [8, 25, 27] have demonstrated the importance of p38 MAPK activity to maintaining PGHS-2 mRNA stability. In the present experiment, actinomycin D was added to BEND cells after 3 h of PdBu treatment, and the PGHS-2 mRNA levels were measured 90 min after addition of actinomycin D. In cells that were treated with or without actinomycin D, PGHS-2 mRNA levels were constant and not different. Simultaneous addition of the p38 MAPK inhibitor and actinomycin D caused a major decrease in PGHS-2 mRNA levels by 90 min. This response indicates that transcription was not required for stabilization of PGHS-2 mRNA by p38 MAPK and that the SB203580-induced degradation of PGHS-2 mRNA was caused by direct inhibition of p38 MAPK. Thus, p38 MAPK appears to sustain mRNA concentrations of PGHS-2.

The present results as well as those of Pru et al. [19] suggest that PdBu induces both ERK/MAPK and p38 MAPK pathways (i.e., PdBu stimulated phosphorylation of p38 MAPK) to increase PGHS-2 mRNA in BEND cells. It may be that the ERK/MAPK pathway is required for PdBu induction of PGHS-2 mRNA expression and p38 MAPK is activated to sustain the stability of PGHS-2 mRNA. These differential effects of ERK/MAPK and p38 MAPK support the conclusions that p38 MAPK activation alone is not enough to induce PGHS-2 expression [5] and that p38 MAPK is involved in PGHS-2 mRNA stability [26].

The second objective of the present study was to investigate if IFN-{tau} exerted a role in posttranscriptional regulation of PGHS-2 mRNA. Studies in BEND cells showed that IFN-{tau} decreased PdBu-stimulated expression of PGHS-2 mRNA by 1 h [19] and that of PGHS-2 protein by 3 h [18]. The IFN-{tau} may be regulating both transcriptional and nontranscriptional mechanisms to exert inhibitory effects on PGHS-2 gene and protein expression as well as secretion of PGF2{alpha}. Pru et al. [19] failed to demonstrate any inhibitory effect of IFN-{tau} on any step of the Raf1/MEK1/ERK1/ 2 pathway. Because the effect of IFN-{tau} on PGHS-2 mRNA is very rapid, examination of the effect of IFN-{tau} on p38 MAPK activation is important as an alternative mechanism of nontranscriptional regulation of PGHS-2 mRNA. Contrary to our hypothesis, Western blots for phosphorylated p38 MAPK revealed that IFN-{tau} also induced phosphorylation of p38 MAPK. Similarly, IFN-{tau} induced phosphorylation and activation of p38 MAPK in bovine primary myometrial cell cultures [41] but also induced PGHS-2 mRNA expression. The IFN-{tau} could have differential effects depending on cell types and the amount of IFN-{tau} used. For example, Parent et al. [42] demonstrated distinct responses to IFN-{tau} (same isoform as that used in the present experiment) depending on the concentration used in primary bovine epithelial cell cultures. At concentrations less than 1 µg/ml, IFN-{tau} suppressed PG secretion, whereas at 20 µg/ml, PG secretion and expression of PGHS-2 were increased. Moreover, Xiao et al. [31] demonstrated in primary cultures that IFN-{tau} decreased PGHS-2 mRNA expression in epithelial cells but increased expression in stromal cells. The IFN-{tau} stimulation of p38 MAPK phosphorylation in BEND cells may be related to some other functional roles of IFN-{tau}. Type I IFNs stimulate p38 MAPK activation in a variety of cell types [43–45]. Uddin et al. [44] demonstrated that the p38 MAPK pathway was required for IFN-{alpha}-dependent transcriptional activation. Moreover, Mayer et al. [43] and Verma et al. [45] indicated a role for p38 MAPK in mediating the growth-inhibitory effects of IFN-{alpha}. Li et al. [46] reported that p38 MAPK activation is required for type I IFN-dependent transcription to mediate IFN responses. It was demonstrated that the p38 MAPK and its downstream effectors are essential for transcription of type I IFN-regulated genes that have ISRE and gamma-activated sequence (GAS) elements in their promoters. Perhaps, IFN-{tau} activation of p38 MAPK leads to expression of a protein, not yet identified, that may cause an increased degradation of PGHS-2 mRNA.

One-hour treatment of cells with IFN-{tau} after previous 3-h stimulation with PdBu was enough to decrease the concentrations of PGHS-2 mRNA. Interestingly, when transcription was blocked by the addition of actinomycin D for 30 min before the addition of IFN-{tau} at 3 h after PdBu stimulation, the inhibitory effect of IFN-{tau} on PGHS-2 mRNA was blocked. Thus, the decrease in PGHS-2 mRNA caused by IFN-{tau} is dependent on transcription. The magnitude of the decrease in the message induced by IFN-{tau} (50 ng/ml) was similar to that caused by addition of p38 MAPK inhibitor. As mentioned previously, PdBu-treated cells with or without actinomycin D had similar PGHS-2 mRNA concentrations. Thus, the IFN-{tau} effect to decrease PGHS-2 was through an increased degradation of the PGHS-2 mRNA and was transcription dependent. This effect was independent of that induced by the inhibition of p38 MAPK, because the p38 MAPK inhibitor acted in the presence of actinomycin D (SB203580 acts in a similar fashion in the absence of actinomycin D; data not shown). The SB203580-induced decrease in stability of PGHS-2 mRNA is attributed to an inhibition in p38 MAPK activity. In contrast, IFN-{tau} induction of an increase in degradation of PGHS-2 mRNA required transcriptional products that are yet to be identified. In the BEND cell model, the transcriptional effect of IFN-{tau} and the nontranscriptional effect of the p38 MAPK inhibitor on degradation of PGHS-2 mRNA ultimately caused additive and independent inhibitory effects on PGF2{alpha} secretion.

Binelli et al. [23] demonstrated that IFN-{tau} induced tyrosine phosphorylation, homo- and heterodimer formation, nuclear translocation, and DNA binding of signal transducer and activator of transcription (STAT) proteins 1, 2, and 3 in BEND cells. Expression of IRF-1 protein was evident at 1 h after IFN-{tau} treatment in BEND cells [23]. The IFN-{tau} induced gene transcription in bovine and ovine uteri [47– 51]. One product of IFN-{tau}-induced transcription is ISG17 [52]. The ISG17 gene encodes a protein, ISG17, which is a 17-kDa ubiquitin homologue. This protein was originally named ubiquitin cross-reactive protein, because it shared amino acid sequence homology with ubiquitin [48]. ISG17 undergoes conjugation with cytosolic uterine proteins [53]. However, to our knowledge, these cytosolic proteins have not yet been identified. Such conjugations may occur with some proteins, which regulate stability of specific mRNAs. Stability of mRNA is regulated by AU-rich sequences within the 3'-untranslated region (UTR) [54], and the PGHS-2 transcript possesses these sequences in the 3'-UTR [33]. Specific proteins, such as HuD, HuR, and AUF1, bind to the 3'-UTR region of mRNAs and regulate their stability either positively or negatively [54–56]. Perhaps an IFN-{tau}-induced protein, such as ISG17, could alter the availability of such proteins, leading to a destabilization or degradation of PGHS-2 mRNA even though p38 MAPK is activated by IFN-{tau}.

Earlier studies indicate that low concentrations of IFN-{tau} inhibit secretion of PGF2{alpha} and expression of PGHS-2 that is reversed by high concentrations of IFN-{tau} [42, 57]. In vivo production of IFN-{tau} is correlated positively with embryo size. Well-developed embryos produce a sufficient amount of IFN-{tau} to inhibit pulsatile secretion of PGF2{alpha} and luteolysis through a block in expression of the oxytocin receptor (OTR) [58, 59]. In maintained pregnancies, expression of PGHS-2 is increased in the bovine endometrium [60, 61]. In pregnant mammals, PGHS-2 is needed for pregnancy-associated events, such as regulation of localized immune function, angiogenesis and regulation of blood flow, and development of implantation sites [62–65]. The increased expression of PGHS-2 is reflected by an increase in basal secretion of PGF2{alpha} in the bovine [66, 67]. The potential to secrete luteolytic pulses, which would antagonize pregnancy in cattle, is abolished by an absence of OTRs because of IFN-{tau} [58, 59]. Xiao et al. [16] documented that even nanogram concentrations of IFN-{tau} could lower oxytocin-binding capability of cultured bovine epithelial cells. Thus, in embryos with low IFN-{tau} secretory potential that are destined to die (i.e., reduced embryo size at Day 17), pulsatile secretion of PGF2{alpha} would be decreased, leading to a temporal delay in luteolysis. Van Cleef et al. [68] reported significant increases in the proportion of heifers with extended cycles that were inseminated but subsequently not diagnosed as pregnant (e.g., experienced embryo mortality) compared to noninseminated cyclic heifers. Consequently, low concentrations of IFN-{tau} would inhibit the pulsatile secretion of PGF2{alpha} via impairment in oxytocin signaling as well as an increase in the degradation of PGHS-2 mRNA. Pregnancy will not be maintained because of an absence of PGHS-2 for implementation of PG-dependent pregnancy processes, but the temporary absence of pulsatile secretion of PGF2{alpha} contributes to a delay in CL regression that is finally overridden by induction of OTR as a default in the absence of IFN-{tau}.

In conclusion, the negative effects of IFN-{tau} on PdBu-induced expression of PGHS-2 mRNA and secretion of PGF2{alpha}in BEND cells seems to be transcription dependent. This effect possibly was exerted partially by increased degradation of the PGHS-2 mRNA in BEND cells. Also, PdBu acts to activate the p38 MAPK pathway along with the ERK/MAPK pathway to stimulate rapid activation of the PG cascade.


   ACKNOWLEDGMENTS
 
The authors would like to thank Dr. R.M. Roberts for providing the recombinant bovine IFN-{tau} and Dr. J. Sirois for providing bovine PGHS-2 cDNA.


   FOOTNOTES
 
1 Supported in part by the NRI Competitive Grant Program/USDA, grant 98-35203-6367. This is Florida Agricultural Experimental Station Journal Series R-10035. Back

2 Correspondence: William W. Thatcher, Department of Animal Sciences, P.O. Box 110920, Gainesville, FL 32611-0910. FAX: 352 392 5595; thatcher{at}animal.ufl.edu Back

Received: 12 November 2003.

First decision: 10 December 2003.

Accepted: 25 February 2004.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996 271:33157-33160[Free Full Text]
  2. Weaver SA, Russo MP, Wright KL, Kolios G, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF{alpha}-induced cyclooxygenase 2 expression in colonic epithelial cells. Gastroenterology 2001 120:1117-1127[CrossRef][Medline]
  3. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993 268:9049-9054[Abstract/Free Full Text]
  4. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. Induction in vivo and in vitro. J Biol Chem 1992 267:11586-11592[Abstract/Free Full Text]
  5. Monick MM, Robeff PK, Butler NS, Flaherty DM, Carter AB, Peterson MW, Hunninghake GW. Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem 2002 277:32992-33000[Abstract/Free Full Text]
  6. Ledinghen VD, Liu H, Zhang F, Lo CR, Subbaramaiah K, Dannenberg AJ, Czaja MJ. Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes. Carcinogenesis 2002 23:73-79[Abstract/Free Full Text]
  7. DeWitt DL, Maeda EA. Serum and glucocorticoid regulation of gene transcription and expression of prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch Biochem Biophys 1993 306:694-102[CrossRef][Medline]
  8. Jang BC, Sanchez T, Schaefers HJ, Trifan OC, Liu CH, Creminon C, Huang CK, Hla T. Serum withdrawal-induced posttranscriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem 2000 275:39507-39515[Abstract/Free Full Text]
  9. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1{alpha}. J Biol Chem 1994 269:11769-11775[Abstract/Free Full Text]
  10. Farin CE, Imakawa K, Hansen TR, McDonnell JJ, Murphy CN, Farin PW, Roberts RM. Expression of trophoblastic interferon genes in sheep and cattle. Biol Reprod 1990 43:210-218[Abstract]
  11. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, Charlier MA, Charpigny SY. IFN-{tau}: a novel subtype I IFN1. Structural characteristics, nonubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998 80:755-777[Medline]
  12. Roberts RM, Ealy AD, Alexenko AP, Han CS, Ezashi T. Trophoblast interferons. Placenta 1999 20:259-264[Medline]
  13. Li J, Roberts RM. Interferon-{tau} and interferon-{alpha} interact with the same receptors in bovine endometrium. J Biol Chem 1994 269:13544-13550[Abstract/Free Full Text]
  14. Meyer MD, Hansen PJ, Thatcher WW, Drost M, Badinga L, Roberts RM, Li J, Ott TL, Bazer FW. Extension of corpus luteum life span and reduction of uterine secretion of prostaglandin F2{alpha} of cows in response to recombinant interferon-{tau}. J Dairy Sci 1995 78:1921-1931[Abstract]
  15. Danet-Desnoyers G, Wetzels C, Thatcher WW. Natural and recombinant bovine interferons regulate basal and oxytocin-induced secretion of PGF2{alpha} and PGE2 by endometrial epithelial and stromal cells. Reprod Fertil Dev 1994 6:193-202[CrossRef][Medline]
  16. Xiao CW, Murphy BD, Sirois J, Goff AK. Down-regulation of oxytocin-induced cyclooxygenase-2 and prostaglandin F synthase expression by interferon-{tau} in bovine endometrial cells. Biol Reprod 1999 60:656-663[Abstract/Free Full Text]
  17. Thatcher WW, Binelli M, Burke J, Staples CR, Ambrose JD, Coelho S. Antiluteolytic signals between the conceptus and endometrium. Theriogenology 1997 47:131-140
  18. Binelli M, Guzeloglu A, Badinga L, Arnold DR, Sirois J, Hansen TR, Thatcher WW. Interferon-{tau} modulates phorbol ester-induced production of prostaglandin and expression of cycloxygenase-2 and phospholipase-A2 from bovine endometrial cells. Biol Reprod 2000 63:417-424[Abstract/Free Full Text]
  19. Pru JK, Rueda BR, Austin KJ, Thatcher WW, Guzeloglu A, Hansen TR. Interferon-{tau} suppresses prostaglandin F2{alpha} secretion independently of the mitogen-activated protein kinase and nuclear factor {kappa}B pathways. Biol Reprod 2001 64:965-973[Abstract/Free Full Text]
  20. Liu J, Antaya M, Boerboom D, Lussier JG, Silversides DW, Sirois J. The delayed activation of the prostaglandin G/H Synthase-2 promoter in bovine granulosa cells is associated with down-regulation of truncated upstream stimulatory factor-2. J Biol Chem 1999 274:35037-35045[Abstract/Free Full Text]
  21. Harada H, Fujita T, Miyamato M, Kimura Y, Maruyama M, Furia A, Miyata T, Tanuguchi T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to same regulatory elements of IFN and IFN-inducible genes. Cell 1989 58:729-739[CrossRef][Medline]
  22. Henderson YC, Chou M, Deisseroth AB. Interferon regulatory factor-1 induces the expression of the interferon-stimulated genes. Br J Haematol 1997 96:566-575[CrossRef][Medline]
  23. Binelli M, Subramaniam P, Diaz T, Johnson G, Hansen TR, Badinga L, Thatcher WW. Bovine interferon-{tau} stimulates the janus kinase-signal transducer and activator of transcription pathway in bovine endometrial epithelial cells. Biol Reprod 2001 64:654-665[Abstract/Free Full Text]
  24. Choi Y, Johnson GA, Burghardt RC, Berghman LR, Joyce MM, Taylor KM, Stewart MD, Bazer FW, Spencer TE. Interferon regulatory factor-2 restricts expression of interferon stimulated genes to the endometrial stroma and glandular epithelium of the ovine uterus. Biol Reprod 2001 65:1039-1049
  25. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK1-SEK1/ MKK4-p38 mitogen-activated protein kinase pathway. J Biol Chem 1998 273:12901-12908[Abstract/Free Full Text]
  26. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxygenase-2 mRNA stability by taxanes. J Biol Chem 2003 278:37637-37647[Abstract/Free Full Text]
  27. Dean JLE, Brook M, Clark AE, Saklatvala J. p38 Mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999 274:264-269[Abstract/Free Full Text]
  28. Reunanen N, Westermarck J, Hakkinen L, Holmstrom TH, Elo I, Eriksson JE, Kahari VM. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998 273:5137-5145[Abstract/Free Full Text]
  29. Chattopadhyay N, Tfelt-Hansen J, Brown EM. PKC, p42/44 MAPK and p38 MAPK regulate hepatocyte growth factor secretion from human astrocytoma cells. Mol Brain Res 2002 102:73-82[Medline]
  30. Guzeloglu A, Binelli M, Badinga L, Hansen TR, Thatcher WW. PKC induction of PGF2{alpha} secretion is dependent upon protein synthesis and regulated by bIFN-{tau}. Biol Reprod 2000 62:suppl 1) 62:260 (abstract 390) [Abstract/Free Full Text]
  31. Xiao CW, Liu JM, Sirois J, Goff AK. Regulation of cyclooxygenase and prostaglandin F synthase gene expression by steroid hormones and interferon-{tau} in bovine endometrial cells. Endocrinology 1998 139:2293-2299[Abstract/Free Full Text]
  32. Staggs KL, Austin KJ, Johnson GA, Teixerra MG, Talbott CT, Dooley VA, Hansen TR. Complex induction of bovine uterine proteins by interferon-{tau}. Biol Reprod 1998 59:293-297[Abstract/Free Full Text]
  33. Liu J, Antaya M, Goff AK, Boerboom D, Silversides DW, Lussier JG, Sirois J. Molecular characterization of bovine prostaglandin G/H synthase-2 and regulation on uterine stromal cells. Biol Reprod 2001 64:983-991[Abstract/Free Full Text]
  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976 72:248-54[CrossRef][Medline]
  35. Dubois DH, Bazer FW. Effect of porcine conceptus secretory proteins on in vitro secretion of prostaglandin-F2{alpha} and -E2 from luminal and myometrial surfaces of endometrium from cyclic and pseudopregnant gilts. Prostaglandins 1991 41:283-301[CrossRef][Medline]
  36. SAS. SAS/STATTM User's Guide (Release 6.03). Cary, NC: SAS institute, Inc.; 1988
  37. Maher P. Phorbol esters inhibit fibroblast growth factor-2 stimulated fibroblast proliferation by a p38 MAP kinase dependent pathway. Oncogene 2002 21:1978-1988[CrossRef][Medline]
  38. Park MJ, Park IC, Hur JH, Kim MS, Lee HC, Woo SH, Lee KH, Rhee CH, Hong SI, Lee SH. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. J Neurosurg 2002 97:112-118[Medline]
  39. Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996 318:325-331
  40. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001 21:771-780[Abstract/Free Full Text]
  41. Doualla-Bell F, Koromilas AE. Induction of PG G/H synthase-2 in bovine myometrial cells by interferon-{tau} requires the activation of the p38 MAPK pathway. Endocrinology 2001 142:5107-5115[Abstract/Free Full Text]
  42. Parent J, Villeneuve C, Alexenko AP, Ealy AD, Fortier MA. Influence of different isoforms of recombinant trophoblastic interferons on prostaglandin production in cultured bovine endometrial cells. Biol Reprod 2003 68:1035-1043[Abstract/Free Full Text]
  43. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-{alpha} in BCR-ABL-expressing cells. J Biol Chem 2001 276:28570-28577[Abstract/Free Full Text]
  44. Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokock Gm, Fish EN, Platanias LC. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon-{alpha}-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000 275:27634-27640[Abstract/Free Full Text]
  45. Verma A, Deb DK, Sassano A, Uddin S, Vargas J, Wickrema A, Platanias LC. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effect of type I interferons and transforming growth factor-ß on normal hematopoiesis. J Biol Chem 2002 277:7726-7735[Abstract/Free Full Text]
  46. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanias LC. Role of p38{alpha} MAP kinase in type I interferon signaling. J Biol Chem 2004 279:970-979[Abstract/Free Full Text]
  47. Austin KJ, Ward SK, Teixeira MG, Dean VC, Moore DW, Hansen TR. Ubiquitin cross-reactive protein is released by the bovine uterus in response to interferon during early pregnancy. Biol Reprod 1996 54:600-606[Abstract]
  48. Austin KJ, Pru JK, Hansen TR. Complementary deoxyribonucleic acid sequence encoding bovine ubiquitin cross-reactive protein: a comparison with ubiquitin and a 15-kDa ubiquitin homologue. Endocrine 1996 5:191-197
  49. Hansen TR, Austin KJ, Johnson GA. Transient ubiquitin cross-reactive protein gene expression in bovine endometrium. Endocrinology 1997 138:5079-5082[Abstract/Free Full Text]
  50. Naivar KA, Ward SK, Austin KJ, Moore DW, Hansen TR. Secretion of bovine uterine proteins in response type I interferons. Biol Reprod 1995 52:848-854[Abstract]
  51. Teixeira MG, Austin KJ, Perry DJ, Dooley VD, Johnson GA, Francis BR, Hansen TR. Bovine granulocyte chemotactic protein-2 is secreted by the endometrium in response to interferon-tau (IFN-{tau}). Endocrine 1997 6:31-37[Medline]
  52. Perry DJ, Austin KJ, Hansen TR. Cloning of interferon-stimulated gene 17: The promoter and nuclear proteins that regulate transcription. Mol Endocrinol 1999 13:1197-1206[Abstract/Free Full Text]
  53. Johnson GA, Austin KJ, Van Kirk EA, Hansen TR. Pregnancy and interferon-{tau} induce conjugation of bovine ubiquitin cross-reactive protein to cytosolic uterine proteins. Biol Reprod 1998 58:898-904[Abstract/Free Full Text]
  54. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of Cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000 20:4265-4274[Abstract/Free Full Text]
  55. Cuadrado A, Navarro-Yubero C, Furneaux H, Kinter J, Sonderegger P, Munoz A. Hud binds to three AU-rich sequences in the 3'-UTR of neuroserpin mRNA and promotes the accumulation of neuroserpin mRNA and protein. Nucleic Acid Res 2002 30:2202-2211[Abstract/Free Full Text]
  56. Laroia G, Schneider RJ. Alternate exon insertion controls selective ubiquitination and degradation of different AUF1 protein isoforms. Nucleic Acid Res 2002 30:3052-3058[Abstract/Free Full Text]
  57. Thatcher WW, Guzeloglu A, Michel F. Bovine endometrial (BEND) cells: molecular and functional responses to phorbol ester and interferon-tau (IFN-{tau}). Biol Reprod 2003 68:suppl 1244 (abstract 320) [Abstract/Free Full Text]
  58. Mann GE, Lamming GE. Relationship between maternal endocrine environment, early embryo development and inhibition of the luteolytic mechanism in cows. Reproduction 2001 121:175-180[Abstract]
  59. Robinson RS, Mann GE, Lamming GE, Wathes DC. The effect of pregnancy on the expression of uterine oxytocin, estrogen, and progesterone receptors during early pregnancy in cow. J Endocrinol 1999 160:21-33[Abstract]
  60. Guzeloglu A, Bilby TR, Kamimura S, Meikle A, Badinga L, Dinges A, Hernandez O, Thatcher WW. Effects of pregnancy and bovine somatotropin (bST) on endometrial estrogen receptor {alpha} (ER-{alpha}), PGHS-2 and PGF2{alpha} secretion on day 17 after estrus in nonlactating dairy cows. Biol Reprod 2002 66:suppl 1314 (abstract 532)
  61. Emond V, MacLaren LA, Kimmins S, Arosh JA, Fortier MA, Lambert RD. Expression of cyclooxygenase-2 and granulocyte-macrophage colony-stimulating factor in the endometrial epithelium of the cow is up-regulated during early pregnancy and in response to intrauterine infusions of interferon-{tau}. Biol Reprod 2004 70:54-64[Abstract/Free Full Text]
  62. Lim H, Paria BC, Das SK, Dinchuk KE, Langenbach R, Trzaskos JM, Dey SK. Multiple female reproductive failure in cyclooxygenase 2-deficient mice. Cell 1997 91:197-208[CrossRef][Medline]
  63. Marions L, Danielsson KG. Expression of cyclooxygenase in human endometrium during the implantation period. Mol Human Reprod 1999 5:961-965[Abstract/Free Full Text]
  64. Matsumoto H, Wen-Ge M, Smalley W, Trzaskos J, Breyer RM, Dey SK. Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation. Biol Reprod 2001 64:1557-1565[Abstract/Free Full Text]
  65. Matsumoto H, Wen-Ge M, Daikoku T, Zhao X, Paria BC, Das SK, Trzaskos JM, Dey SK. Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice. J Biol Chem 2002 277:29260-29267[Abstract/Free Full Text]
  66. Williams WF, Lewis GS, Thatcher WW, Underwood CS. Plasma 13,14-dihydro-15-keto-PGF2{alpha} (PGFM) in pregnant heifers prior to and during surgery and following intrauterine injection of PGF2{alpha}. Prostaglandins 1983 25:891-899[CrossRef][Medline]
  67. Mishra DP, Meyer HHD, Prakash BS. Validation of a sensitive enzyme immunoassay for 13,14-dihydro-15-keto-PGF2{alpha} in buffalo plasma and its application for reproductive health status monitoring. Anim Reprod Sci 2003 78:33-46[CrossRef][Medline]
  68. Van Cleeff J, Drost M, Thatcher WW. Effects of postinsemination progesterone supplementation on fertility and subsequent estrous responses of dairy heifers. Theriogenology 1991 36:795-807[CrossRef][Medline]



This article has been cited by other articles:


Home page
 EndocrinologyHome page
S.-Z. Wang and R. M. Roberts
Interaction of Stress-Activated Protein Kinase-Interacting Protein-1 with the Interferon Receptor Subunit IFNAR2 in Uterine Endometrium
Endocrinology, December 1, 2004; 145(12): 5820 - 5831.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
A. Guzeloglu, T. R. Bilby, A. Meikle, S. Kamimura, A. Kowalski, F. Michel, L. A. MacLaren, and W. W. Thatcher
Pregnancy and Bovine Somatotropin in Nonlactating Dairy Cows: II. Endometrial Gene Expression Related to Maintenance of Pregnancy
J Dairy Sci, October 1, 2004; 87(10): 3268 - 3279.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
71/1/170    most recent
biolreprod.103.025411v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar